<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081597</url>
  </required_header>
  <id_info>
    <org_study_id>ACANTHAS-P1-101</org_study_id>
    <nct_id>NCT04081597</nct_id>
  </id_info>
  <brief_title>A Study of Single Ascending Doses of STAR-101 in Healthy Participants</brief_title>
  <official_title>A Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of STAR-101 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acanthas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acanthas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include a single ascending dose approach to evaluate the safety, tolerability,&#xD;
      and pharmacokinetic properties of STAR-101 after a single oral administration in healthy&#xD;
      participants&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Change in Clinical Strategy&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline to approximate 70 days</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs) will be reported in the Adverse Events module</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with other (non-serious) adverse events</measure>
    <time_frame>Baseline to approximate 70 days</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs) will be reported in the Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration time curve (AUC0 to t-last)</measure>
    <time_frame>Predose up to 144 hours post dose</time_frame>
    <description>AUC from time zero to last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration time curve (AUC0-24)</measure>
    <time_frame>Predose up to 24 hours postdose</time_frame>
    <description>AUC from time zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration time curve (AUC0-inf)</measure>
    <time_frame>Predose up to 144 hours post dose</time_frame>
    <description>AUC from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>Predose up to 144 hours post dose</time_frame>
    <description>Cmax of STAR-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Predose up to 144 hours post dose</time_frame>
    <description>Tmax of STAR-101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QTc interval</measure>
    <time_frame>Predose up to 144 hours post dose</time_frame>
    <description>QTc interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>STAR-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses in two of three crossover periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo in one of three periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Star-101</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>STAR-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male participants who are not vasectomized for at least 6 months and having a&#xD;
             female partner of childbearing potential (childbearing potential females are defined&#xD;
             as women that are neither post-menopausal nor surgically sterile) must agree to use a&#xD;
             reliable method of birth control&#xD;
&#xD;
               1. Simultaneous use of a male condom and, for the female partner, hormonal&#xD;
                  contraceptives (used since at least 4 weeks) or intra-uterine contraceptive&#xD;
                  device(placed since at least 4 weeks) or abstain from sexual intercourse from&#xD;
                  start of study drug dosing until 90 days after dosing with study drug&#xD;
&#xD;
               2. Simultaneous use of a male condom and, for the female partner, a diaphragm or&#xD;
                  cervical cap with intravaginally applied spermicide from start of study drug&#xD;
                  dosing until 90 days after dosing with study drug&#xD;
&#xD;
               3. Male participants (including vasectomized males) with a pregnant partner must&#xD;
                  agree to use a condom from start of study drug dosing until 90 days after dosing&#xD;
                  with study drug&#xD;
&#xD;
               4. No contraception is required for a vasectomized male, provided his vasectomy was&#xD;
                  performed 6 months or more prior to screening and his female partner is not&#xD;
                  pregnant, and for a male participant with a female partner of non-childbearing&#xD;
                  potential.&#xD;
&#xD;
               5. A male who was vasectomized less than 6 months prior to screening must follow the&#xD;
                  same restrictions as a non-vasectomized male&#xD;
&#xD;
               6. Males participants must not donate sperm at any time from start of study drug&#xD;
                  dosing until 90 days after study drug dosing&#xD;
&#xD;
          -  Healthy female participants must be nonpregnant and not lactating. Female participants&#xD;
             of childbearing potential with a non-sterile male partner (sterile male partners are&#xD;
             defined as men vasectomized since at least 6 months) must be willing and able to&#xD;
             practice effective contraception from the period described below and for at least 30&#xD;
             days after the study completion. For this study, acceptable contraception includes:&#xD;
&#xD;
               1. Simultaneous use of intrauterine contraceptive device, without hormone release&#xD;
                  system, placed at least 4 weeks prior to study drug dosing, and cond om for the&#xD;
                  male partner&#xD;
&#xD;
               2. Simultaneous use of diaphragm or cervical cap with intravaginally applied&#xD;
                  spermicide and male condom for the male partner, started at least 21 days prior&#xD;
                  to study drug dosing&#xD;
&#xD;
               3. Sexual abstinence if this is usual and preferred lifestyle choice of participant&#xD;
&#xD;
          -  Have a body mass index of greater than or equal to (≥18.5) and less than &lt;30.0&#xD;
             kilogram - meter squared (kg/m2) and body weight ≥50.0 kilograms (kg) for males and&#xD;
             ≥45.0 kg for females&#xD;
&#xD;
          -  Have given informed consent prior to any study specific- procedures.&#xD;
&#xD;
          -  Are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow Clinical Research Unit (CRU) specific- study procedures.&#xD;
&#xD;
          -  Have clinical laboratory test results within normal reference range for the population&#xD;
             or Investigator site, or results with acceptable deviations that are judged not&#xD;
             clinically significant by the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to study drug dosing,&#xD;
             administration of a biological product in context of a clinical research study within&#xD;
             90 days prior to study drug dosing, or currently enrolled in any other type of medical&#xD;
             research judged not to be scientifically or medically compatible with this study&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating STAR-101&#xD;
&#xD;
          -  Have a clinically significant history or presence of medical illness including, but&#xD;
             not limited to, any cardiovascular, hepatic, respiratory, hematological, endocrine,&#xD;
             psychiatric, immunological, gastrointestinal, renal, metabolic or neurological&#xD;
             disease, convulsions, or any clinically significant laboratory abnormality that, in&#xD;
             the judgment of the investigator, indicate a medical problem that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  Have an abnormality in the 12-lead ECG that, in the opinion of the Investigator,&#xD;
             increases the risks associated with participating in the study. In addition,&#xD;
             participants with the following findings will be excluded:&#xD;
&#xD;
               1. Confirmed Frederica's corrected QT (QTcF) interval greater than ( &gt;) 450 msec&#xD;
                  (milliseconds)&#xD;
&#xD;
               2. Personal or family history (in a first degree relative) of QT prolongation.&#xD;
&#xD;
          -  Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV&#xD;
             antibodies, hepatitis C and/or positive hepatitis C antibody, or hepatitis B and/or&#xD;
             positive hepatitis B surface antigen&#xD;
&#xD;
          -  Have donated plasma within 7 days prior to study drug dosing or have donated or lost&#xD;
             blood from to 50 (milliliter) mL to 499 mL within 30 days, or more than 499 mL within&#xD;
             56 days prior to study drug dosing&#xD;
&#xD;
          -  Are unwilling to stop alcohol and caffeinated beverage consumption for the restriction&#xD;
             periods stated&#xD;
&#xD;
          -  Use of tobacco or nicotine products within 3 months prior&#xD;
&#xD;
          -  Have a history of significant alcohol abuse within 1 year prior or an average weekly&#xD;
             alcohol intake that exceeds 14 units per week (1 unit = 12 ounces (oz) or 360 mL of&#xD;
             beer; 5oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)&#xD;
&#xD;
          -  Have an abnormal blood pressure (supine) defined as diastolic blood pressure &gt;90 or&#xD;
             &lt;50 (millimeters of mercury (mmHg) and/or systolic blood pressure &gt;140 or &lt;90 mmHg&#xD;
             and/or heart rate&gt;100 bpm or &lt;50 (beats per minute) bpm&#xD;
&#xD;
          -  Have following abnormal laboratory results&#xD;
&#xD;
               1. Alanine transaminase (ALT) or aspartate transaminase (AST) &gt;1.5x upper limit of&#xD;
                  normal (ULN)&#xD;
&#xD;
               2. Hemoglobin, white blood cell count, platelets, c-reactive protein, or glucose&#xD;
                  outside or the normal range&#xD;
&#xD;
               3. Creatinine above the ULN.&#xD;
&#xD;
          -  Participants with a history of drug abuse, considered clinically significant, within 1&#xD;
             year prior to screening or use of soft drugs(such as marijuana) within 3 months prior,&#xD;
             or hard drugs (such as cocaine, phencyclidine, crack, opioid derivatives including&#xD;
             heroin, and amphetamine derivatives) within 1 year prior, or who test positive for&#xD;
             drugs of abuse&#xD;
&#xD;
          -  Clinically significant illness or surgery within 4 weeks of study drug dosing&#xD;
&#xD;
          -  History of significant allergic reaction or hypersensitivity to any drug&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Use of medications for the timeframes specified below, with the exception of&#xD;
             medications exempted on a case-by-case basis because they are judged unlikely to&#xD;
             affect the pharmacokinetic profile of the study drug or participant safely (for&#xD;
             example (e.g.), topical drug products without significant systemic absorption):&#xD;
&#xD;
               1. Prescription medications within 14 days prior to study drug dosing&#xD;
&#xD;
               2. Over-the-counter products and natural health products (including herbal remedies&#xD;
                  such as St. John's wort, homeopathic and traditional medicines, probiotics, food&#xD;
                  supplements such as vitamins, minerals, amino acids, essential fatty acids, and&#xD;
                  protein supplements used in sports) within 7 days prior to study drug dosing,&#xD;
                  with the exception of occasional use of acetaminophen (up to 2 grams (g) daily)&#xD;
&#xD;
               3. Depot injection or implant of any drug within 3 months prior to study drug dosing&#xD;
&#xD;
               4. Any drugs known to induce or inhibit hepatic drug metabolism within 30 days prior&#xD;
                  to dosing&#xD;
&#xD;
          -  Any reason which, in the opinion of the investigator, would prevent the participant&#xD;
             from participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acanthas Pharma</last_name>
    <role>Study Director</role>
    <affiliation>Acanthas Pharma</affiliation>
  </overall_official>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

